This investigation is being undertaken in the RAINBO clinical trial program, wherein patients with stage II/III endometrial cancer are being randomly assigned to receive radiation therapy alone or radiation therapy combined with durvalumab (PD-L1 inhibitor) [115]. This evidence concerns the gene CD274 and endometrial cancer.